A multi-national, open-labelled, randomised, parallel group, 4 week run-in and 26 weeks treat-to-target comparison of biphasic insulin aspart 30 once daily versus insulin glargine once daily both in combination with metformin and glimepiride in insulin naïve subjects with type 2 diabetes. Trial Phase: 4
Latest Information Update: 05 Oct 2021
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary) ; Glimepiride; Insulin glargine; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms OnceMix
- Sponsors Novo Nordisk
- 23 Jun 2012 Official Title amended as reported by European Clinical Trials Database record.
- 23 Jun 2012 Planned number of patients changed from 481 to 700 as reported by European Clinical Trials Database record.
- 03 Oct 2009 The results of this study were presented the 45th Annual Meeting of the European Association for the Study of Diabetes, according to a Novo Nordisk media release.